Abstract: Disclosed herein, in one aspect, is a method of treating B cell driven autoimmune and allergic diseases, such as lupus, comprising administering to a patient in need thereof an effective amount of B cell inhibitor that is non-depletional.

Abstract: Disclosed herein, in one aspect, is a method of reducing immunogenicity, comprising administering to a patient receiving or having received a biological therapeutic agent, an effective amount of B cell inhibitor that is non-depletional. Related compositions are also provided.

Abstract: A transaction and identity verification system includes a processor and a memory including computer program code, where executing the computer program code by the processor causes the transaction and identity verification system to utilize a private permissioned distributed ledger to qualify users for different capabilities within the system, and verify identities and purchase eligibilities of system customers.

Abstract: Disclosed herein, in one aspect, is a method of reducing immunogenicity, comprising administering to a patient receiving or having received a biological therapeutic agent, an effective amount of B cell inhibitor that is non-depletional. Related compositions are also provided.

Abstract: A financial regulatory compliance platform includes a processor, a memory including computer program code, wherein executing the computer program code by the processor causes the financial regulatory compliance platform to utilize a rules engine to verify transaction data from a business client against a set of compliance rules to determine financial regulatory compliance, upon determining financial regulatory compliance, provide a notification of compliance to a financial institution receiving the transaction data, and upon determining financial regulatory non-compliance, provide a notification of non-compliance to the financial institution.